Cancer clinical trials in the region Île-de-France

787 currently recruiting clinical trials
Region Île-de-France
Phase 1 / Phase 2 Breast cancer #NCT05986071
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Targeted therapy Hormone therapy
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
1 recruiting site
Institut Paoli Calmettes
Phase 1 / Phase 2 Sarcoma and GIST #NCT07602777 #2025-523997-18-00
Required histologic types
Bone sarcoma Soft tissue sarcoma
Required histologic sub types
Osteosarcoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Endometrial cancer #NCT06796907 #2024-517147-31-00
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06796907 #2024-517147-31-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Serous low grade carcinoma (LGSOC) Endometrioid carcinoma Clear cell carcinoma Mucinous carcinoma Other epithelial ovarian cancer
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT06638502 #2025-523630-59-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
HepaRegeniX GmbH
Phase 1 / Phase 2 Stomach and esophageal cancer #NCT06780111 #2024-514273-22-00
Required histologic types
Esophagus
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT05768139 #2023-000442-41
Required histologic types
Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses
Required histologic sub types
Squamous cell carcinoma
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy
1 2 3 or more
6 recruiting sites
Eli Lilly et compagnie
Phase 1 / Phase 2 Lymphoma CLL & Richter's syndrome Acute leukemia Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT07220616 #2025-522595-87-00
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
3 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Breast cancer #NCT03424005 #2017-002038-21
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy
2 recruiting sites
Hoffmann-La Roche
Phase 1 / Phase 2 Prostate cancer #NCT04104776 #2023-508002-20-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals